AGBL2 and asthma: Although the rates of anti–CCP‐2 positivity were not significantly different between BR patients and controls (Table 2), the titers of anti–CCP‐2 antibodies in BR patients were significantly increased compared with those in both healthy controls (P < 0.001) and patients with asthma (P < 0.01) (Figure 1).